By Ron Zapata ( April 24, 2007, 12:00 AM EDT) -- Despite objections by Novartis Pharmaceutical Corp., a district court has allowed plaintiffs who allege the pharmaceutical giant's bone cancer drugs cause jawbone decay to divide into a proposed class seeking dental monitoring and a group seeking personal injury damages, the plaintiffs' lawyer said Tuesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.